The case for & against
Bull & Bear analysis
Bullish
Exelixis, Inc. (NASDAQ: EXEL) is a leading biotechnology company specializing in the development and commercialization of therapies for cancer treatment, primarily focusing on solid tumors. Its flagship product, Cabozantinib, is recognized for its effectiveness in renal cell carcinoma (RCC) and neuroendocrine tumors. Exelixis is actively advancing its pipeline with Zanzalitinib (ZANZA) and emphasizes strong market positioning via innovative therapeutic solutions to meet unmet medical needs in oncology.
Bull says
- ↑Cabozantinib U.S. revenues rose 36% YoY to $513M in Q1 2026
- ↑Consensus FY 2026 EPS estimates raised to $3.53, driven by strong revisions
- ↑Exelixis holds a 46% share of the RCC TKI market
- ↑GAAP net income of $210.5M in Q1 2026, reflecting robust profitability
- ↑December PDUFA for Zanzalitinib could materially boost future revenues
- ↑$1.4B cash on hand and high earnings yield support financial flexibility
Bear says
- ↓Negative book-to-price ratio indicates potential overvaluation
- ↓Pipeline uncertainty: Zanzalitinib approval delays could stall growth
- ↓No dividend yield; share repurchases may limit R&D funding
- ↓Intense competition in TKIs risks eroding market share
- ↓Rising short interest reflects growing bearish sentiment
- ↓Regulatory and execution risks in clinical trials could derail pipeline
Investment themes with EXEL
Buybacks↑ +0.48%
Companies repurchasing their own shares
C · JCI · WFC
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT
Demographics: Elderly Care↓ -0.26%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q1 2025 · Mgmt. Guidance
Updated 05-28-2026bullish
Transcript signals
Bull points
- we are on track to file up to three INDs this year
- we filed the IND for XB628 in the first quarter of this year and the phase one trial is now open and recruiting
- As a first-in-class molecule with an innovative mechanism of action, XB628 has created a lot of excitement with the principal investigators of the Phase I trials
Bear points
- we've decided to discontinue the development program for XL495 due to drug-related toxicities, indicating challenges in maintaining a viable therapeutic index for this compound
Read full transcript analysis ›